Literature DB >> 2509411

The pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin in a rat abscess model.

E Leibovitz1, G Keren, M Shabtai, A Barzilai, E Rubinstein.   

Abstract

The penetration, pharmacokinetics and therapeutic efficacy of fleroxacin and pefloxacin were investigated in a rat abscess model. Abscesses were induced by implanting a dialysis tube unit contaminated with Serratia marcescens in the subcutaneous tissue. Simultaneous serum, interstitial fluid (IF) and abscess fluid concentrations of the investigated antibiotics were measured 24 and 96 h after implantation. The concentrations were determined at various time intervals after the last intramuscular administration of each drug (20 mg/kg). Peak fleroxacin and pefloxacin concentrations in the serum of the infected animals were 14.6 +/- 4.7 mg/l and 13 +/- 2.9 mg/l respectively, peak fleroxacin and pefloxacin abscess fluid concentrations after 24 h were 12.3 +/- 2.5 mg/l and 8.9 +/- 2.2 mg/l, respectively (85% and 68% of peak serum concentrations). Abscess fluid concentrations at 96 h were: fleroxacin 4.7 +/- 2.6 mg/l and pefloxacin 4.5 +/- 1.7 mg/l. Both antimicrobials persisted significantly longer in the abscess fluid than in serum. Both drugs failed to sterilize the abscesses following a single administration; however after four consecutive administrations all abscesses became sterile. We conclude that fleroxacin and pefloxacin may be suitable for the therapy of closed space infections caused by susceptible micro-organisms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2509411     DOI: 10.1093/jac/24.3.375

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  7 in total

Review 1.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  Activity of fleroxacin alone and in combination with clindamycin or metronidazole in experimental intra-abdominal abscesses.

Authors:  A Pefanis; C Thauvin-Eliopoulos; J Holden; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

3.  Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.

Authors:  A J Fischman; E Livni; J W Babich; N M Alpert; A Bonab; S Chodosh; F McGovern; P Kamitsuka; Y Y Liu; R Cleeland; B L Prosser; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; J A Correia; H W Strauss
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

5.  In vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia.

Authors:  P H Edelstein; M A Edelstein; B Holzknecht
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

Review 6.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

7.  Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; R J Callahan; J A Correia
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.